Evidence map›Paper›PMID 41760981›Full record

SynthesisArchives of gynecology and obstetrics2026

Unlocking ovarian rejuvenation with platelet-rich plasma: systematic review and proposed clinical framework for Controlled use in poor prognosis patients undergoing in vitro fertilisation.

Arwa A Alageel

Abstract readSystematic Review
In one paragraph

Synthesis in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Arwa A AlageelClinical Laboratories Science, College of Applied Medical Science, King Saud University, P.O. Box 2455, 11451, Riyadh, Saudi Arabia. aaalageel@ksu.edu.sa.

Funding

King Saud University OFR-2025-1347
6 · The paper itself

Abstract

backgroundPlatelet-rich plasma (PRP) is used as an adjunctive treatment in various medical fields, including orthopaedics, plastic surgery, dermatology, and wound healing. However, PRP application in reproductive medicine, particularly for fertility restoration, remains controversial, specifically for women with diminished ovarian reserve (DOR), premature ovarian insufficiency (POI), and pre-menopause. This systematic review aimed to comprehensively evaluate the existing literature on autologous PRP use for ovarian rejuvenation, with a focus on refining and standardising PRP protocols and identifying appropriate candidate populations.

methodsA comprehensive literature search was conducted on the autologous PRP use using Cochrane, Embase, PubMed, MEDLINE, NCBI, and Google Scholar databases. Studies on PRP application in reproductive medicine were identified and classified into two categories: DOR and POI. The PRP preparation protocol was assessed, and the results were compared. This narrative systematic review, carried out in compliance with PRISMA 2020 guidelines, combined results, although meta-analysis was not feasible due to significant variation in study design, PRP preparation, and outcome measures.

resultsSeveral studies reported restoration of menstruation following intraovarian PRP administration in women with POI. In women with DOR, studies reported changes in ovarian reserve markers, including increases in serum anti-Müllerian hormone (AMH) levels and reductions in follicle-stimulating hormone (FSH) levels; however, these changes were not consistently associated with higher antral follicle counts or oocyte yield. Instead, sseveral studies reported higher proportions of mature oocytes and pregnancy and live birth outcomes, particularly following repeated PRP treatment cycles in women with long-standing ovarian dysfunction.

conclusionsIntraovarian PRP may have a potential role in activating dormant follicles in a selected subset of women with poor ovarian response. However, the current evidence remains limited and heterogeneous, supporting its use only within structured clinical or research protocols until higher-quality, standardised studies are available.

Indexed as

Fertilization in VitroOvarian ReserveOvaryPlatelet-Rich PlasmaPrimary Ovarian InsufficiencyRejuvenationFemaleHumansMenopause, PrematurePregnancyPrognosisAssisted reproductionIVF treatmentPlatelet-rich plasmaPoor fertility outcomesPoor ovarian responsePremature ovarian insufficiency

Identifiers

PMID41760981
PMCPMC12948781

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.